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Dual-probe molecular MRi for 
the in vivo characterization of 
atherosclerosis in a mouse model: 
Simultaneous assessment of plaque 
inflammation and extracellular-
matrix remodeling
carolin Reimann1,2, Julia Brangsch1,2, Jan O. Kaufmann1,3,4, Lisa C. Adams  1, 
David C. onthank5, Christa thöne-Reineke  2, Simon P. Robinson5, Bernd Hamm1, 
Rene M. Botnar  6,7,8,9 & Marcus R. Makowski1,6,8
Molecular MRi is a promising in-vivo modality to detect and quantify morphological and molecular 
vessel-wall changes in atherosclerosis. The combination of different molecular biomarkers may improve 
the risk stratification of patients. This study aimed to investigate the feasibility of simultaneous 
visualization and quantification of plaque-burden and inflammatory activity by dual-probe molecular 
MRI in a mouse-model of progressive atherosclerosis and in response-to-therapy. Homozygous 
apolipoprotein e knockout mice (Apoe−/−) were fed a high-fat-diet (HfD) for up to four-months prior 
to MRI of the brachiocephalic-artery. To assess response-to-therapy, a statin was administered for 
the same duration. MR imaging was performed before and after administration of an elastin-specific 
gadolinium-based and a macrophage-specific iron-oxide-based probe. Following in-vivo MRI, samples 
were analyzed using histology, immunohistochemistry, inductively-coupled-mass-spectrometry and 
laser-inductively-coupled-mass-spectrometry. In atherosclerotic-plaques, intraplaque expression 
of elastic-fibers and inflammatory activity were not directly linked. While the elastin-specific probe 
demonstrated the highest accumulation in advanced atherosclerotic-plaques after four-months of HFD, 
the iron-oxide-based probe showed highest accumulation in early atherosclerotic-plaques after two-
months of HFD. In-vivo measurements for the elastin and iron-oxide-probe were in good agreement 
with ex-vivo histopathology (elastica-van-Giesson stain: y = 298.2 + 5.8, R2 = 0.83, p < 0.05; Perls‘ 
prussian-blue-stain: y = 834.1 + 0.67, R2 = 0.88, p < 0.05). Contrast-to-noise-ratio (CNR) measurements 
of the elastin probe were in good agreement with icp-MS (y = 0.11x-11.3, R² = 0.73, p < 0.05). 
Late stage atherosclerotic-plaques displayed the strongest increase in both CNR and gadolinium 
concentration (p < 0.05). The gadolinium probe did not affect the visualization of the iron-oxide-probe 
and vice versa. This study demonstrates the feasibility of simultaneous assessment of plaque-burden 
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and inflammatory activity by dual-probe molecular MRI of progressive atherosclerosis. The in-vivo 
detection and quantification of different MR biomarkers in a single scan could be useful to improve 
characterization of atherosclerotic-lesions.
Atherosclerosis is the leading cause of morbidity and mortality in the Western world and developing countries1. The 
development of atherosclerosis is a complex process with a dynamic influx of proinflammatory cells and a progres-
sive increase of plaque-burden, which is associated with de-novo synthesis of extracellular-matrix proteins2.
Atherosclerosis progresses relatively slowly and, in most cases, remains asymptomatic until the end-stage of 
the disease. Sudden surface erosion or plaque rupture can lead to vascular occlusion and ischemia, resulting in 
myocardial infarction or cerebral stroke3.
In a clinical setting, conventional angiographic techniques are used to assess the degree of luminal narrowing 
in the coronary and carotid-arteries4. Even though angiographic techniques are the diagnostic reference standard, 
there is growing evidence, that the interventional treatment of the atherosclerotic-plaque, associated with the highest 
degree of stenosis, does not improve the prognosis in all patients5. Furthermore, previous research demonstrated 
that the highest number of ruptured atherosclerotic-plaques were found in arteries with <60% of stenosis6.
Substantial progress has been made with invasive and non-invasive imaging methods in the quest for the “vul-
nerable plaque” in recent years. It is well established, that features of vulnerable plaques go beyond the severity of 
vascular stenosis7. There is a combination of plaque features, which are strongly associated with plaque vulnera-
bility, including the influx of proinflammatory cells, positive vascular-remodeling, angiogenesis, a large necrotic 
core, a thin fibrotic cap, micro-calcifications and plaque hemorrhage.
In this context several invasive and noninvasive imaging techniques have been investigated, but none has been 
widely adopted in in clinical practice.
Inflammatory activity and plaque-burden, which can both be visualized by molecular MRI techniques, were 
established as key features of vulnerable atherosclerotic-plaques. Therefore, the combined assessment of two dif-
ferent plaque characteristics in one scan has the potential to improve the stratification of patients at risk for 
myocardial infarction or cerebral stroke8. So far, a combined assessment of two features (inflammatory activity, 
plaque-burden) in a single scan has not been established in the context of atherosclerosis. This study aimed 
to investigate the feasibility of a simultaneous characterization of the plaque-burden and inflammatory activ-
ity by dual-probe molecular MRI in a mouse-model of progressive atherosclerosis and in response-to-therapy. 
For the visualization of the extracellular-matrix we used a gadolinium-based elastin-specific agent, for the vis-
ualization of proinflammatory cells we used a clinically approved iron-oxide agent Feraheme (Ferumoxytol, 
AMAG-Pharmaceuticals, Waltham, MA, USA). There are a couple of applications with simultaneous use of 
Gd-based and iron-oxide -based imaging probes. They demonstrate that high-resolution magnetic resonance 
imaging (MRI) allows combining cellular-scale resolution with the ability to detect two cell types simultaneously 
at any tissue depth9,10.
Materials and Methods
Animals. This study was performed according the local guidelines and provisions for the implementation of 
the Animal Welfare Act and regulations of the Federation of Laboratory Animal Science Associations (FELASA). 
The regulatory authority the Regional Office for Health and Social Affairs Berlin (LAGeSo) approved this animal 
study. We used eight weeks old apolipoprotein-E-deficient (ApoE−/−) male mice. ApoE−/− mice were fed with a 
high-fat-diet (HFD) containing 21% fat from lard, supplemented with 0.15% (wt/wt) cholesterol (Special-Diets-
Services, Witham, UK) at the age of two-months. A control group with nine 26 week old male C57BL/6J mice 
was used. Statin-treatment was performed in a subgroup of ApoE−/− mice (n = 9) and started in parallel with the 
feeding of the HFD feeding. Pravastatin (Kemprotec-Limited, Middlesbrough, UK) was administered at a dose 
of 40 mg/kg body-weight/day via drinking water. Please refer to Supplementary Fig. 1 for the experimental setup 
and for further details to the Supplementary Material.
Gadolinium-based elastin-specific agent. In this study we used a low molecular weight 
gadolinium-based (856 g/mol molecular-mass) elastin-specific MR agent. A rapid clearance from the blood-pool 
via the kidneys and highest binding can be measured 30 to 45 minutes following the administration11,12. For 
the unbound and bound agent, a longitudinal-relaxivity of 4.68 ± 0.13 mM−1s−1 and 8.65 ± 0.42 mM−1s−1 was 
reported, which is higher than for clinical used agents, such as gadobutrol11,12. This probe was validated and 
used in different previous studies to visualize the extracellular-matrix (ECM) protein, elastin11,12. The in-vivo 
visualization of the ECM protein elastin in atherosclerotic-plaque represents a surrogate marker for overall 
plaque-burden11,12. In this study, the elastin-specific probe was administered via the tail vein at a clinically used 
dose of 0.2 mmol/kg on days one of MRI examination and after 24 h on day two of MRI examination.
Iron-oxide-based macrophage-specific agent. The iron-oxide-particle used in this study is coated with 
semisynthetic carbohydrate (ferumoxytol). Because of its effectiveness in shortening T1 and T2 relaxation times 
this agent was developed as a MRI agent initially13. Ferumoxytol (Feraheme®, AMAG-Pharmaceuticals, Waltham, 
MA, USA) was approved by the Food-and-Drug-Administration (FDA) for iron-deficiency-anemia treatment in 
adults with chronic-kidney- disease (CKD) in 2009. In recent years the use of off-label iron-oxide nanoparticle as 
a MRI probe by clinicians and researchers has grown13. A linear dependence of R1, R2, and R2* on ferumoxytol 
concentration was found in saline and plasma with lower R1 values at 3.0 T and similar R2 and R2* values at 
3.0 T (r1saline = 10.0 ± 0.3smM; r1plasma = 9.5 ± 0.2smM; r2saline = 62.3 ± 3.7smM; r2plasma = 65.2 ± 1.8smM; r2*sa-
line = 57.0 ± 4.7smM; r2*plasma = 55.7 ± 4.4smM)14. In this study, ferumoxytol was administered at the clinical dose 
(4 mg Fe/kg) via the tail vein injection and imaging was performed after 24-hours.
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In-vivo MR Experiments. Imaging sessions were performed at a clinical 3T Siemens system (Biograph, 
Siemens Healthcare, Erlangen, Germany) with a single loop coil (diameter 4 cm) with mice in prone position. 
For details regarding the T1-weighted and T2*-weighted sequences please refer to the Supplementary Material.
Assessment of magnetic resonance imaging signal. Evaluation of the gadolinium-based elastin-specific 
probe on T1-weighted sequences. The quantification of the MRI signal was conducted using OsiriX (OsiriX 
Foundation, Geneva, Version5.6). To assess the lumen and arterial-wall including the atherosclerotic-plaque, 
time-of-flight (TOF) images were automatically co-registered and overlaid with high–resolution MRI images. 
Morphometric measurements were implemented on high–resolution MRI images. Regions of interest (ROIs) 
were co–localized with the atherosclerotic-plaque (highest signal within the arterial wall) and defined as areas 
of enhancement on high–resolution MRI images. We calculated the contrast-to-noise-ratio with following 
equation: CNR = (Combined vessel-wall and atherosclerotic-tissue-signal − Blood-signal)/Noise. The noise 
was defined as the standard deviation in pixel intensity from a ROI placed in the background air anterior to 
brachiocephalic-artery.
Quantification of iron-oxide on T2*-weighted sequences. MR images of the vessel-lumen areas were compared 
between pre-contrast T2*-weighted MR images prior and iron-oxide injection 24 h post injection. All data orig-
inated from T2*-weighted images are demonstrated the signal-loss area (%) in relating to the pre-contrast MRI 
scan. To compare areas of signal-void within the ROI identical window and level settings were used. The areas 
were established semi-automatically using identic 2D-segmentation parameters.
Histological analysis and immunofluorescence of the arterial vessel system and plaque mor-
phometry. Please refer to the Supplementary Material.
inductively coupled mass spectrometry for quantification of gadolinium and iron and 
Laser-inductively-coupled-mass-spectrometry (LA ICP-MS) for spatial localization of gadolinium. 
Please refer to the Supplementary Material.
Competition experiments. Please refer to the Supplementary Material.
Statistical analysis. Please refer to the Supplementary Material.
Results
Multi-target plaque characterization in a single MR imaging session. Simultaneous imaging of the 
elastin-specific gadolinium-based probe and the macrophage-specific iron-oxide-based probe. This study demon-
strates that MR plaque-imaging with two probes can be performed in a single imaging session (Fig. 1). Using a 
combination of gadolinium-based elastin-specific imaging and iron-oxide-based macrophage-specific imaging 
different phases of atherosclerotic-plaque development and response-to-therapy could be evaluated. More spe-
cifically, de novo synthesis of elastic-fibers and inflammatory activity were not directly linked in atherosclerot-
ic-plaques. In the early-stage of plaque development after two-months of high-fat-diet, only a small increase in 
de-novo elastin synthesis was observed (14% of the maximum after four-months of high-fat-diet) in the ather-
osclerotic-plaque. In contrast, a marked increase in iron-oxide-particle accumulation was measured (45% of 
Figure 1. Multitarget characterization of the plaque-burden and inflammatory activity by molecular MRI. (A) 
Time-of-flight-angiography showing the aortic-arch, brachiocephalic-artery, subclavian-artery and carotid-
arteries of an ApoE−/− mice after four-months of high-fat-diet. (B) T1-weighted-imaging pre-contrast (B1, B4) 
and following the administration of the gadolinium-based elastin-specific MR-probe (B2, B5) at the clinical 
dose of 0.2 mmol/kg. Automatic image-fusion (B3, B6) demonstrates the localization of the signal from the 
MR-probe in the vascular-wall in relation to the blood signal (B4). (C) T2*-weighted-imaging prior to and 
following the administration of the iron-oxide-probe (ferumoxytol) at the clinical dose of 4 mg Fe/kg. On 
pre-contrast images, the vascular lumen can be clearly delineated for circular shape (C1). 24-hours following 
the administration of the iron-oxide-particle, a clear signal-void reduces the signal from the lumen can be 
visualized (C2), reflecting the accumulation of the iron-oxide-particles in atherosclerotic-plaques.
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maximum after four-months of high-fat-diet), indicating a strong inflammatory response in the early-stage of the 
disease. In advanced atherosclerotic-plaques,the influx of macrophages was most pronounced after four-months 
of high-fat-diet and in the most advanced plaques. In agreement with this abundant deposition of elastic-fibers in 
the plaque matrix was measured. This indicates, that in advanced plaques strong ECM-remodeling is accompa-
nied by a large influx of pro-inflammatory macrophages.
In response to statin-treatment a different relative response was measured regarding the expression of 
elastic-fibers and the influx of macrophages. The amount of elastin detectable with ESMA was decreased by 43% 
compared to the four-months high-fat-diet group, while the influx of macrophages showed an even more pro-
nounced decrease of 73% compared to the four-months high-fat-diet group.
T1-weighted MR imaging for the assessment of the gadolinium-based elastin-specific 
MR-probe. In all mice, including those on high-fat-diet and the statin-treatment, a low CNR was measured 
in the brachiocephalic vessel-wall at all time-points on non-contrast-enhanced (pre-contrast) MR scans (Fig. 2A). 
A minor increase in CNR was measured in the two-months’ scans and a strong increase in the four-months’ 
scans After administration of the elastin-specific MR-probe (Fig. 2A). The measured CNR (Fig. 2A) was lower 
for mice with the statin treatment and differed to the non-treated four-months-HFD mice. A strong correla-
tion was measured between the CNR and the density of elastic-fibers on Elastica-von-Gieson-staining in the 
atherosclerotic-plaque (y = 289.2x + 5.8, R² = 0.83, p ≤ 0.05, Fig. 2B).
T2*-weighted MR imaging for the assessment of macrophage-specific iron-oxide- 
particles. ApoE−/− and control mice cross-sectional T2*-weighted images of brachiocephalic-artery 
demonstrated a circulary lumen prior to the administration of the iron-oxide contrast agent ferumoxytol 
(Fig. 1). Increasing regions of signal-loss were detected in brachiocephalic-plaques in ApoE−/− mice on two 
and four-months of HFD after 24-hours after ferumoxytol injection. Area of signal-loss was continuous and 
Figure 2. In vivo MRI signal measurements and ex vivo quantification of gadolinium-based and iron-
oxide-based molecular probes. (A) Average atherosclerotic-plaque CNR pre–contrast and following the 
administration of the gadolinium-based elastin-specific MR-probe. After the injection of the elastin-specific 
probe, a small increase (p ≤ 0.05) in atherosclerotic-plaque CNR could be observed, while a strong increase in 
plaque CNR could be observed after four-months of HFD. (B) In the scatter-plot, the in vivo measured CNR 
showed a strong correlation (p ≤ 0.05) with the ex vivo Elastica-van-Giesson-staining. (C) After two-months 
of high-fat-diet a strong accumulation (p ≤ 0.05) of iron-oxide-particles could be observed. After four-months 
of high-fat-diet, the most pronounced peak (p ≤ 0.05) was measured. In response to the statin-treatment, a 
strong reduction (p ≤ 0.05) in iron-oxide-particle accumulation. (D) In the scatter-plot, the in vivo measured 
signal-void resulting from the iron-oxide-particles showed a strong correlation (p ≤ 0.05) to the ex vivo Perls’-
Prussian-blue-stain.
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constituted a substantial percentage of the luminal area. There was no effect detected in the control group. After 
two and four-months of HFD an increase in percent signal-loss (relative to pre-contrast MRI) was detected with 
plaque-progression (26.7 ± 8.3%, 47 ± 9.6%, p ≤ 0.05). Less pronounced signal-loss was detected in the statin 
treatment group compared to animals on four-months of HFD (18 ± 3.6%, p ≤ 0.05). A strong correlation existed 
between the area loss on T2* and the accumulation of the iron-oxide-particles on Perl’s staining (y = 834.1x + 0.7, 
R² = 0.88, p ≤ 0.05, Fig. 2D).
Influence of the gadolinium-based elastin-specific probe on the visualization of iron-oxide- 
particles and vice versa. When using a dual-probe approach, it is of high clinical importance that the 
gadolinium-based and iron-oxide-based probe do not affect the visualization and quantification of the 
respective other probe. Therefore, we evaluated the influence of the gadolinium-based probe on the assess-
ment of iron-oxide-particle measurements. 24-hours after the administration of the iron-oxide-particle 
T2*-weighted-imaging was performed prior to and 45 min following a dose of the elastin-specific probe in ani-
mals after four-months of high-fat-diet (n = 9). The assessment of iron-oxide-particles on T2*-weighted images 
prior to a dose of the gadolinium-based probe demonstrated a strong correlation with measurements following 
a dose of the gadolinium-based probe (y = 0.77x + 3.2, R² = 0.92, p ≤ 0.05, Fig. 3A). Between both acquisitions 
no significant differences (p > 0.05) were measured. To investigate the influence of the iron-oxide-particles on 
the assessment of the elastin-specific agent on T1-weighted images, imaging was performed on day one prior 
to and 24-hours following the administration of the iron-oxide-particles (n = 9). The CNR measurements of 
elastin-specific MR-probe showed a strong correlation between both days (y = 0.95x + 2.54, R² = 0.94, Fig. 3B). 
Between both days no significant difference (p > 0.05) was measured. This indicates that the gadolinium-based 
and iron-oxide-based probe do not affect the visualization and quantification of the respective other probe at 
these time-points.
Histology and Immunofluorescence. Elastin in the extracellular-matrix. Ex-vivo measurements 
on histological slices were in good agreement with in-vivo measurements using the elastin-specific probe 
(y = 289.2x + 5.8, R² = 0.83, p ≤ 0.05). After two-months of high-fat-diet, a slight, but already significant 
(p ≤ 0.05) gain in signal was measured (Fig. 2). After four-months of high-fat-diet, the increase in elastic-fibers in 
the extracellular matrix of the atherosclerotic-plaque was even stronger (p ≤ 0.05) (Fig. 2) but in response to the 
statin-treatment, a significant (p ≤ 0.05) decrease in the expression of elastic-fibers was observed (Fig. 2).
Macrophages in the atherosclerotic-plaque. To demonstrated the presence of macrophages in the 
atherosclerotic-lesions a CD68 staining was used (Fig. 4D1–4). With increasing duration of the HFD an increase 
in %macrophages and %Perls’ Prussian-blue-staining (R2 = 0.88, p ≤ 0.05) was observed (Fig. 2D). In the 
statin-group, a significant (p ≤ 0.05) decrease in positive macrophages areas was measured, which was in agree-
ment with a intense decrease in areas positive for iron. Perls’ Prussian-blue-stain was negative for iron-oxide 
depositions without a prior iron-oxide injection in mice four-months on HFD.
Gadolinium concentration by inductively-coupled mass-spectrometry (ICP-MS). From early to 
advanced phases of disease progression the average concentration of gadolinium in the brachiocephalic-artery 
wall gained substantially (n = 15, Fig. 5). A significant correlation between ex-vivo measured gadolinium con-
centrations (ICP-MS) and CNR (p < 0.05) was found (Fig. 5A). Also, for iron-oxide-particles, a significant 
Figure 3. Influence of the gadolinium-based elastin-specific probe on the visualization of iron-oxide-particles 
and vice versa. If a multi-target approach is chosen, it is of high clinical importance, that the respective imaging 
probes do not affect the measurements on the other probe. (A) To investigate the influence of iron-oxide-
particles on the assessment of the elastin-specific-agent on T1-weighted images, imaging was performed on 
day one prior to the administration of the iron-oxide-particles and 24-hours following the administration of 
the iron-oxide-particles. CNR-measurements of the elastin-specific MR-probe showed a strong correlation 
between both days. (B) To investigate the influence of the gadolinium-based probe on the assessment of the 
iron-oxide-particles on T2*-weighted-sequences, imaging was performed on day two prior to and following 
the administration of the elastin-specific probe. The assessment of the effect of iron-oxide-particles on T2*-
weighted images prior to the administration of the gadolinium-based probe demonstrated a strong correlation 
with measurements following the administration of the gadolinium-based probe.
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correlation between the absolute iron-oxide quantity in the brachiocephalic-artery by ICP-MS and T2* measure-
ments (R2 = 0.73, p < 0.05, Fig. 5B) was observed.
Spatial localization of the gadolinium-based elastin-specific probe using laser coupled mass 
spectrometry (LA-ICP-MS). We investigated arterial-wall samples of animals after four-months of 
high-fat-diet (n = 3) and mapped the dispersion of the gadolinium by LA-ICP-MS to define the gadolinium dis-
persion within the arterial-wall after the administration of the elastin-specific probe,. Co–localization of targeted 
gadolinium with elastic-fibers was determined (Fig. 6B, n = 3).
Competition experiments. To reaffirm the specific binding of the elastin-specific molecu-
lar agent an in-vivo competition experiment was performed. A pre-injection of a tenfold-higher-dose of 
non-paramagnetic-europium-labeled elastin-specific MR-probe resulted in a distinct decrease of CNR differs to 
the application of the gadolinium-labeled elastin-specific agent. Between pre-contrast scans on days one and two 
no significant differences were measured. The in-vivo competition experiments were performed in ApoE−/− mice 
(n = 3) on a four-month’s high-fat-diet (Fig. 6A).
Discussion
This study demonstrates the feasibility of multi-probe molecular MRI for the simultaneous characterization 
of extracellular-matrix remodeling and inflammatory activity in a mouse-model of progressive atheroscle-
rosis. There was a temporal delay between de-novo synthesis of elastic-fibers and inflammatory activity in 
atherosclerotic-plaques. While inflammation was more pronounced in early atherosclerotic-plaques and showed 
a stronger response to statin therapy, elastin deposition was highest in advanced atherosclerotic-plaques.
This is the first in-vivo MR study to demonstrate that both ECM-remodeling and inflammation can be visual-
ized and quantified using a multi-probe approach in a single MR examination. Additionally, it was demonstrated 
that the gadolinium-based and iron-oxide-based probe do not affect each other and thus visualization and quan-
tification of the respective targets was not compromised.
The simultaneous in-vivo detection and quantification of inflammation and ECM-remodeling could be useful 
for an improved characterization and staging of coronary and carotid atherosclerotic-lesions, which may aid 
in-vivo characterization of the disease, including the assessment of response-to-therapy.
Figure 4. Multitarget characterization of the plaque-burden and inflammatory activity by molecular MRI 
at different phases of plaque development and in response-to-therapy. (A–C) Cross-sectional histological/
immunofluorescence sections (A1-4: Elastica-van-Giesson stain, B1-4: Perls’-Prussian-blue-stain, C1-4: 
Immunofluorescence-macrophage-stain) of brachiocephalic-arteries of control and ApoE−/− mice two-months, 
four-months of HFD and statin-treatment. (D,E) T1 and T2*-weighted-imaging with corresponding histology. 
D1-4: On T1-weighted sequences, a significant increase of vessel-wall-enhancement is in the vessel wall, 
corresponding to an increased elastin deposition in atherosclerotic-plaque after four-months of HFD. Only a 
slight increase can be visualized after two-months and following statin-treatment. E1-4: A pronounced signal-
void can already be seen after two-months of high-fat-diet, reflecting an already pronounced accumulation of 
iron-oxide-particles in the atherosclerotic-plaque. The most pronounced signal-void can be observed after four-
months of high-fat-diet with almost 50% of the vascular lumen affected by the signal-void. Following statin-
treatment, a comparable signal-void to the two-months group is visualized. (A–D) Scale corresponds to 100 µm. 
(E,F) Scale corresponds to 500 µm.
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Figure 5. In vivo MRI signal measurements and ex vivo quantification of molecular probes. (A) The scatter-
plots show a strong correlation between in vivo CNR and results from ICP–MS of brachiocephalic-arteries. (B) 
The scatter-plot shows a strong correlation between the signal-void on the T2*-weighted-sequences with the 
results from ICP-MS. (C) The immunofluorescence-staining of the macrophage area using an antibody (CD68-
Antibody) cause a strong correlation (p ≤ 0.05) with the signal-void on the T2*-weighted-sequences.
Figure 6. Competition experiments and laser ICP-MS for the mapping of the gadolinium distribution in an 
atherosclerotic-plaque. (A) First a pre-contrast scan was acquired on day one. In the next step 0.2 mmol/kg of 
the gadolinium-based elastin-specific probe was administered to assess the uptake of the probe in the vessel-
wall. After 24-hours, a pre-contrast scan was repeated to confirm the washout of the agent. For the competition 
experiments, a tenfold-higher dose of non-paramagnetic europium-labeled elastin-specific MR-probe was 
administered prior to the application of 0.2 mmol/kg of the gadolinium-based elastin-specific probe. This 
resulted in a marked decrease of the contrast-to-noise-ratio compared to the administration of the gadolinium 
labeled elastin-specific agent alone. The in vivo competition experiments were performed in ApoE−/− mice 
(n = 3) on a four-months high-fat-diet. (B) Spatial localization of the gadolinium-based elastin-specific probe 
using LA-ICP-MS. Signal from gadolinium across the arterial-wall sample (n = 3) was mapped to determine the 
distribution of gadolinium. Co–localization of targeted gadolinium with elastic-fibers was found.
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Multi-probe plaque characterization using an elastin-specific gadolinium-based probe and a 
macrophage-specific iron-oxide-based probe. Elastic-fibers play an important role during the patho-
genesis of atherosclerosis15. Besides their elastic properties, elastic-fibers also have molecular signaling functions 
in atherosclerosis, influencing cell proliferation/migration and the retention of lipoproteins15.
Inflammation is considered to be a main drivers of atherosclerosis and especially macrophages are thought to 
play a central role16. Lipoproteins lead to a recruitment of monocytes/macrophages into the subendothelial space, 
where these cells phagocytose accumulating lipoproteins17.
The initiation and progression of atherosclerotic-plaques is a highly complex process, in which various cellular 
and matrix associated processes occur simultaneously. Different features that are associated with plaque vulner-
ability can be imaged based on the different available imaging techniques. In recent years, especially the visual-
ization and quantification of vascular-remodeling and inflammation have been shown to represent promising 
biomarkers for improving the prediction of plaque vulnerability and the associated clinical events18.
Atherosclerosis associated vascular-remodeling is a process during which arteries enlarge to compen-
sate for the development of the atherosclerotic-plaque. In the context of atherosclerosis, this process was first 
described and quantified by Glagov et al.5. The noninvasive quantification of vascular-remodeling was shown 
to be a highly promising biomarker to identify early subclinical disease, for the detection of unstable plaque 
and to monitor the progression and regression of atherosclerosis, e.g. in response-to-therapy. In this context, 
optical-coherence-tomography (OCT) and intravascular-ultrasound (IVUS) studies demonstrated that positive 
vascular-remodeling is a relevant feature of vulnerable atherosclerotic-plaques19. Previous studies have shown 
that the elastin-specific gadolinium-based probe used in the present study could be used to visualize elastin in 
the arterial-wall and that it may be used as a surrogate marker for plaque-burden and vascular-remodeling11,12. 
Gadolinium-based probes are visualized as a result of the shortening of the T1-relaxation-times, resulting in a 
bright signal on T1-weighted images.
Various preclinical and clinical studies have investigated the use of iron-oxide-particles for the visualization 
of intraplaque macrophages20. In the clinical setting, iron-oxide-particle accumulation in atherosclerotic-plaques 
correlated with the number of intraplaque macrophages21. It was also shown that ruptured or rupture prone plaques 
show a significantly higher accumulation of iron-oxide-particles compared to stable lesions. Regarding the assess-
ment of response-to-therapy, the ATHEROMA study demonstrated, that the response to statin’s anti-inflammatory 
effects could be assessed using iron-oxide-particles22. Iron-oxide-particles are visualized as a result of the shortening 
of the local T2/T2*-relaxation-times, creating a detectable signal-void on T2/T2*-weighted images.
For the visualization of the different probes, we used specific sequences. It however has to be considered that 
T1 and T2 probes also have minor effects on the T2 and T1 relaxation, especially if probes which exhibit a strong 
effect on both, T1 and T2 relaxation, are used.
This was also the first study, directly investigating the temporal association between intraplaque inflam-
mation and extracellular-matrix remodeling in a single scan. In the current study, we could demonstrate that 
plaque inflammation and extracellular-matrix remodeling show a different temporal evolution during plaque 
development. In the early-phase, a pronounced accumulation of iron-oxide-particles was observed, which was 
in good agreement with a strong inflammatory process as shown by histology. In advanced plaques, a strong 
expression of elastic-fibers was observed. In response-to-therapy, a pronounced reduction in the accumulation 
of iron-oxide-particles was measured. These findings indicate that the development of atherosclerotic-plaque 
in this model is characterized by an early inflammation process, followed by cell migration and finally by 
extracellular-matrix remodeling (as typically seen in tissue injury such as myocardial infarction). There was no 
direct temporal association between extracellular-matrix remodeling and inflammation.
The use a two probes at the same time could be associated with challenges regarding a broad clinical translation. 
However, in the context of PET/MR imaging two probes (e.g. Gadovist and FDG) are also used in combination for 
tumor detection. The advantage of dual probe MR imaging would be the lack of ionizing radiation in this context.
An additional important finding of this study was that the gadolinium-based and iron-oxide-based probe 
used in these experiments do not affect the visualization and quantification of the respective other probe, which 
is especially relevant in a clinical setting.
Translational potential of this study. The gadolinium-based molecular probe used in this study was 
administered at a clinical dose and the molecular-weight and signal properties of the probe are comparable to 
currently used clinical contrast-agents. The applied iron-oxide-particle (also used at a clinical dose) is clinically 
approved is currently successfully used as an imaging-agent in a clinical setting. Results from this study can be 
directly translated to human applications, using the same dose and with identical relaxation/rotational-correlation 
properties of the probes used.
Mouse-model used in this study. Previous studies have demonstrated that the brachiocephalic-artery of 
the ApoE−/− mouse-model exhibits a consistent rate of lesion development/progression and that lesions show 
comparable features as observed during the different stages of plaque development in humans23. A main limita-
tion of animal models in general is, that they never fully resemble human disease.
conclusion
This study demonstrates the feasibility of a simultaneous dual-probe molecular MRI for the simultaneous char-
acterization of plaque-burden and inflammatory activity by in a mouse-model of progressive atherosclerosis. The 
in-vivo detection and quantification of these biomarkers associated with plaque instability in a single scan may 
enable the detection of potentially unstable plaque and thereby improve risk stratification and guidance of treat-
ment and allow to monitor treatment response.
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Data Availability
The datasets generated and analysed during the current study are available from the corresponding author on 
reasonable request.
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